Logo

Call us today 212-583-0100

ir@enzo.com    

  • Home
  • Corporate
    • Investor Information
    • About Us
    • Officers & Directors
    • Press Releases
    • Careers
  • Therapeutics
    • About ENZO Therapeutics
      • Overview
      • Our Mission
      • Our Strategy
      • Partnering
      • Maps and Directions
      • Contact Us
    • Therapeutic Market
      • Overview
      • Inflammatory Bowel Disease
      • Uveitis
      • HIV
      • Bone Disorders
      • Diabetes
    • Technologies
      • Immune Regulation
      • Gene Technology
      • Cell Signaling Modulation
    • Pipeline
      • Overview
      • Cell Signaling Modulation
        • Diabetes
        • Preclinical Studies for Bone Disorders
      • Immune Regulation
        • Alequel ™
        • Optiquel ™
      • Gene Technology
        • Stealth Vector™ HGTV43™
  • Clinical Labs
  • Life Sciences
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Dec 12, 2022 5:29pm EST

Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update

Dec 07, 2022 6:18pm EST

Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th

Nov 08, 2022 6:04pm EST

Enzo Biochem, Inc. Announces Date of Annual Shareholders’ Meeting

Oct 20, 2022 8:15am EDT

Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO

Oct 14, 2022 7:30am EDT

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Oct 10, 2022 11:31am EDT

Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th

Oct 06, 2022 8:00am EDT

Enzo Biochem, Inc. Opens Expanded Life Sciences Laboratory and Office Facilities in Farmingdale, New York

Sep 26, 2022 8:00am EDT

Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2

Aug 11, 2022 8:00am EDT

Enzo Biochem to Launch Monkeypox Testing Services this Week

Aug 03, 2022 8:00am EDT

Enzo Biochem Appoints Matthew Kupferberg as General Counsel

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …32
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed

Meta

  • Privacy Policy
  • Intellectual Property
  • Safe Harbor Statement
  • HIPAA Policy
  • Web Feedback

Contact us

Enzo Biochem Executive Offices
81 Executive Blvd, Suite 3
Farmingdale, NY
11735
USA

212-583-0100

info@enzo.com

Copyright ©2023 Enzo Biochem Inc.